文章：

肝细胞癌系统性药物治疗的潜在预测性生物标志物：临床实践中的预期应用价值

Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice

原文发布日期：30 August 2023

DOI: 10.3390/cancers15174345

类型: Article

开放获取: 是

英文摘要：

In the systemic drug treatment of hepatocellular carcinoma, only the tyrosine kinase inhibitor (TKI) sorafenib was available for a period. This was followed by the development of regorafenib as a second-line treatment after sorafenib, and then lenvatinib, a new TKI, proved non-inferiority to sorafenib and became available as a first-line treatment. Subsequently, cabozantinib, another TKI, was introduced as a second-line treatment, along with ramucirumab, the only drug proven to be predictive of therapeutic efficacy when AFP levels are >400 ng/mL. It is an anti-VEGF receptor antibody. More recently, immune checkpoint inhibitors have become the mainstay of systemic therapy and can now be used as a first-line standard treatment for HCC. However, the objective response rate for these drugs is currently only 30% to 40%, and there is a high incidence of side effects. Additionally, there are no practical biomarkers to predict their therapeutic effects. Therefore, this review provides an overview of extensive research conducted on potential HCC biomarkers from blood, tissue, or imaging information that can be used in practice to predict the therapeutic efficacy of systemic therapy before its initiation.

摘要翻译： 

在肝细胞癌的系统性药物治疗中，曾有一段时间仅有酪氨酸激酶抑制剂索拉非尼可供使用。随后瑞戈非尼作为索拉非尼的二线治疗方案被研发问世，而新型酪氨酸激酶抑制剂仑伐替尼经证实疗效不劣于索拉非尼，成为可选的一线治疗药物。此后，另一酪氨酸激酶抑制剂卡博替尼作为二线治疗方案进入临床，同时获批的还有雷莫西尤单抗——这是目前唯一被证实当甲胎蛋白水平>400 ng/mL时能预测疗效的药物，该药物为抗血管内皮生长因子受体抗体。近年来，免疫检查点抑制剂已成为系统性治疗的主流方案，目前可作为肝细胞癌的一线标准治疗。然而，这类药物的客观缓解率目前仅为30%至40%，且副作用发生率较高。此外，尚无实用的生物标志物可预测其治疗效果。因此，本综述概述了从血液、组织或影像学信息中筛选潜在肝细胞癌生物标志物的广泛研究，这些标志物可在临床实践中用于预测系统性治疗的疗效。

原文链接：

Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice